4D Molecular Therapeutics Cuts Workforce By 25% In July 2025 To Save $15M Annually, Extend Cash Runway Into 2028
Benzinga Newsdesk 1 year ago
NewsManagement
Implemented a workforce reduction of approximately 25% of current and planned roles in July 2025, primarily in the areas supporting early-stage research and development and support functions.The workforce reduction is
- Implemented a workforce reduction of approximately 25% of current and planned roles in July 2025, primarily in the areas supporting early-stage research and development and support functions.
- The workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and BLA preparation, which supports the Company's cash runway into 2028, as previously guided.